GSK delivers improvements in sales, margins and cash flow in 2017:Total EPS 31.4p, +67% AER, +36% CER; Adjusted EPS 111.8p, +11% AER, +4% CER
GSK China and Ali Health jointly announced a strategic partnership to launch an innovative adult vaccination service system. The system will include online disease education and consultation, online HCP appointment booking, and deliver convenient online-to-offline (O2O) end-to-end service for users. Moreover, community healthcare service centres nationwide can utilise this platform to manage vaccination enquiries and requests. This will help enhance efficiency at the centres and help reduce costs and workload, thus optimising public healthcare institutions’s resources. By year-end, the platform is expected to cover 1500 community healthcare service centres in more than one hundred cities nationwide, including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing and Wuhan.
It’s been a big year in healthcare technology. Healthcare Analytics News™ reached out to experts across our 8 coverage areas to determine which companies, people, and projects made the biggest waves. The winners of 2017 ushered in advances that have turned heads, resulted in measurable improvements, and given reason to believe that this high-speed sector is not built on hype alone.
AstraZeneca and Imperial College London have announced plans to work together on investigating the scientific mechanisms and underlying drivers of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD).
Researchers investigated whether mepolizumab is safer and more effective than triple-inhaled treatments for chronic obstructive pulmonary disease.
Respiratory system drugs is a term used to describe a wide variety of medicines used to relieve, treat, or prevent respiratory diseases such as asthma, chronic bronchitis, chronic obstructive pulmonary disease (COPD), or pneumonia. Today, Ddu, the leading global pharmaceutical & medical device B2B online platform, will share China’s Import and Export Market Report of Respiratory System Drugs with you.
Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
The US Food and Drug Administration (FDA) has cleared Adherium for its new inhaler monitoring device for AstraZeneca’s Symbicort aerosol inhaler.
GlaxoSmithKline and Innoviva have unveiled data from a second ground-breaking Salford Lung Study (SLS) showing that Relvar Ellipta significantly improved asthma control versus patients’ standard therapy.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.